Computer System Launched To Manage Blood Screening Data
By LabMedica International staff writers Posted on 21 Oct 2008 |
A computer system was launched that improves laboratory efficiency by managing test data when screening donated blood for hepatitis and retroviruses.
The new system will enable laboratories to track and trend quality control and performance of blood-screening assays and will provide laboratories with robust data capabilities through expanded archival features. It also will help blood-screening laboratories manage retesting of samples, produce reports, and generate statistical charts.
Called the Abbott Prism Director, the new system was launched by Abbott (Abbott Park, IL, USA) at the American Association of Blood Banks annual meeting on October 7, 2008, in Montreal, Canada. The Abbott Prism is an automated immunoassay analyzer designed to perform in vitro diagnostic donor screening for hepatitis and retroviruses. The analyzer is used by blood, plasma, organ, and tissue centers in more than 30 countries to screen more than 40 million donations each year.
"The worldwide launch of the Abbott Prism Director brings an important new product to our expanding portfolio of blood-screening systems and assays and demonstrates our continued commitment to blood-screening laboratories and the overall safety of the blood supply,” said James Stewart, Ph.D., director of research and development, Abbott Diagnostics. "For testing facilities that use multiple or single Abbott Prism instruments, the Abbott Prism Director offers data management functionality that can significantly enhance laboratory operations.”
Abbott is a global leader in in vitro diagnostics and provides a broad range of instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices, and clinics. The company's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility.
Related Links:
Abbott
The new system will enable laboratories to track and trend quality control and performance of blood-screening assays and will provide laboratories with robust data capabilities through expanded archival features. It also will help blood-screening laboratories manage retesting of samples, produce reports, and generate statistical charts.
Called the Abbott Prism Director, the new system was launched by Abbott (Abbott Park, IL, USA) at the American Association of Blood Banks annual meeting on October 7, 2008, in Montreal, Canada. The Abbott Prism is an automated immunoassay analyzer designed to perform in vitro diagnostic donor screening for hepatitis and retroviruses. The analyzer is used by blood, plasma, organ, and tissue centers in more than 30 countries to screen more than 40 million donations each year.
"The worldwide launch of the Abbott Prism Director brings an important new product to our expanding portfolio of blood-screening systems and assays and demonstrates our continued commitment to blood-screening laboratories and the overall safety of the blood supply,” said James Stewart, Ph.D., director of research and development, Abbott Diagnostics. "For testing facilities that use multiple or single Abbott Prism instruments, the Abbott Prism Director offers data management functionality that can significantly enhance laboratory operations.”
Abbott is a global leader in in vitro diagnostics and provides a broad range of instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices, and clinics. The company's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility.
Related Links:
Abbott
Latest Technology News
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read more
Key Gene Identified in Common Heart Disease Unlocks Life-Saving Diagnostic Potential
Hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary heart disease globally, affecting approximately 1 in 200 individuals, and remains a leading cause of heart transplantation.... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more